# YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Source: https://onco.cc/trials/nct05767892/  
OnCo record `nct05767892` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pemetrexed, carboplatin and cisplatin in lung cancer, run by Suzhou Puhe Pharmaceutical Technology Co., LTD, not yet recruiting.

## Summary

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations is a phase 3, randomised interventional study registered as NCT05767892 by Suzhou Puhe Pharmaceutical Technology Co., LTD, with a registry enrolment figure of 350 participants, started 2023-05-01 and due to reach its primary completion in 2025-07-30. Interventions recorded: YK-209A tablet; Pemetrexed+carboplatin/Cisplatin. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). Primary outcome: Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .. Lung eligibility wording from the registry: "Histologically or cytologically confirmed nonsquamous cell locally advanced not suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05767892
- Phase: 3
- Setting: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
- Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT05767892: https://clinicaltrials.gov/study/NCT05767892

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05767892.json